AdventHealth partners with Helix for a 10,000-patient DNA sequencing trial
WholeMe is the first genomics project by AdventHealth (AH), to partner with Helix.
It is a clinical trial to sequence DNA of 10,000 Floridians.
Goal is to better prevent, diagnose, and treat diseases, like hypercholesterolemia.
Helix uses Next Generation Sequnecing (NGS) to sequence a proprietary assay called Exome+.
That provides 100 times more data than was previously available.
Helix will sequence each participant’s DNA sample once, then securely store information.
This enables user to explore many DNA-powered applications throughout their lifetime.
AH recruited any adult 18 or older, and located in the central Florida community.
They can withdraw consent any time and request anonymity and deletion of genetic data.
To include small subgroup of 750 people that already had experienced a cardiac event.
In attempt to determine if genetic testing and the counseling can improve their cases.
Currently, no scheduled end date yet, and at 67 percent of its recruitment goal.
Mentioned in this article:
AdventHealth - Multi-state health care network
Exome+ - proprietary approach sequencing technology, Helix
Helix - American population genomics company
LifeOmic - Software company
Rebecca Essner - Data scientist and geneticist at AdventHealth
Steven Smith - Chief Scientific Officer, AdventHealth